Home

Our team, with financial and scientific support from the Public Health Agency of Canada (PHAC), will develop six evidence-based guidelines on post-COVID-19 condition using rigorous scientific methods. Our goal is to use the best available evidence to provide clinicians, decision-makers, policymakers, and the public in Canada with detailed guidance to make informed health decisions about post-COVID-19 condition (PCC). We intend to prioritize topics that are most important to these audiences through a careful and inclusive process, while also considering the needs of equity-deserving groups.

This project aims to identify and address discrepancies and overlaps in medicine recommendations and indications between the WHO Essential Medicines List (EML) and WHO guidelines, to inform strategies that enhance WHO EML-guideline alignment, increase the EML’s responsiveness, and enhance equitable access to and use of essential medicines in global and national healthcare decision-making.

As part of the European Commission’s Joint Research Center (JRC) in the context of the European Commission Initiative on Colorectal Cancer (ECICC), we coordinated a systematic review of analytical frameworks concerning ColoRectal Cancer (CRC). We also coordinated a systematic overview of CRC guidelines and recommendations with a mapping exercise of possible questions that may be relevant for CRC prevention, screening, and diagnosis. Further work is being done to develop an analytical framework for the ECICC CRC guideline.

Cochrane Canada launched eCOVID-19 RecMap, or COVID-19 Recommendation Map and Gateway to Contextualization, an interactive, easy-to-navigate, living, and freely accessible online repository of quality-appraised COVID-19 recommendations. This CIHR-funded resource is made freely available to guide clinicians, policymakers, and citizens in response to the pandemic.

MacGRADE Centre and Cochrane Canada faculty and staff have been leading living systematic reviews for living practice guidelines on the use of anticoagulation for prevention of thrombosis in COVID-19 patients, as commissioned by the American Society of Hematology since 2020, and this work is still ongoing. Several methodological innovations have been used during this process, including steps to optimize the living process, the use of machine learning to improve the feasibility of screening a large body of evidence, and the application of decision thresholds.